{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:37:12Z","timestamp":1792816632109,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007877","name":"Fujita Health University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["25ym0126817"],"award-info":[{"award-number":["25ym0126817"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bbrc.2026.154629","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:12:54Z","timestamp":1790205174000},"page":"154629","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Enhanced NRF1-mediated proteasome bounce-back and nelfinavir-mediated bortezomib sensitization in gemcitabine\/cisplatin-resistant bladder cancer cells"],"prefix":"10.1016","volume":"838","author":[{"given":"Atsumi","family":"Ota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rin","family":"Himura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sota","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomofumi","family":"Saka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8382-0526","authenticated-orcid":false,"given":"Yuta","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4513-5035","authenticated-orcid":false,"given":"Goki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7189-0376","authenticated-orcid":false,"given":"Tadayuki","family":"Tsujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2696-0897","authenticated-orcid":false,"given":"Akira","family":"Ikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0578-9672","authenticated-orcid":false,"given":"Satoshi","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2026.154629_bib1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev.biochem.78.081507.101607","article-title":"Recognition and processing of ubiquitin-protein conjugates by the proteasome","volume":"78","author":"Finley","year":"2009","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bbrc.2026.154629_bib2","doi-asserted-by":"crossref","first-page":"5599","DOI":"10.1158\/0008-5472.CAN-05-0201","article-title":"Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue","volume":"65","author":"Chen","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154629_bib3","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1073\/pnas.87.18.7071","article-title":"Abnormally high expression of proteasomes in human leukemic cells","volume":"87","author":"Kumatori","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.bbrc.2026.154629_bib4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma","volume":"127","author":"Jagannath","year":"2004","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bbrc.2026.154629_bib5","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.2217\/fon.14.30","article-title":"Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials","volume":"10","author":"Huang","year":"2014","journal-title":"Future Oncol."},{"key":"10.1016\/j.bbrc.2026.154629_bib6","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.cell.2017.04.023","article-title":"The logic of the 26S proteasome","volume":"169","author":"Collins","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2026.154629_bib7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.molcel.2010.02.029","article-title":"Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells","volume":"38","author":"Radhakrishnan","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbrc.2026.154629_bib8","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.cub.2014.06.004","article-title":"Proteasome-mediated processing of Nrf1 is essential for coordinate induction of all proteasome subunits and p97","volume":"24","author":"Sha","year":"2014","journal-title":"Curr. Biol."},{"key":"10.1016\/j.bbrc.2026.154629_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00439-16","article-title":"A homeostatic shift facilitates endoplasmic reticulum proteostasis through transcriptional integration of proteostatic stress response pathways","volume":"37","author":"Baird","year":"2017","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.bbrc.2026.154629_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-41492-9","article-title":"The transcription factor NRF1 (NFE2L1) activates aggrephagy by inducing p62 and GABARAPL1 after proteasome inhibition to maintain proteostasis","volume":"13","author":"Hatanaka","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2026.154629_bib11","article-title":"Bortezomib-encapsulated dual responsive copolymeric nanoparticles for gallbladder cancer targeted therapy","volume":"9","author":"Chen","year":"2022","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.bbrc.2026.154629_bib12","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.01856","article-title":"p97-dependent retrotranslocation and proteolytic processing govern formation of active Nrf1 upon proteasome inhibition","volume":"3","author":"Radhakrishnan","year":"2014","journal-title":"eLife"},{"key":"10.1016\/j.bbrc.2026.154629_bib13","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.18357","article-title":"The aspartyl protease DDI2 activates Nrf1 to compensate for proteasome dysfunction","volume":"5","author":"Koizumi","year":"2016","journal-title":"eLife"},{"key":"10.1016\/j.bbrc.2026.154629_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109775","article-title":"Nelfinavir inhibits human DDI2 and potentiates cytotoxicity of proteasome inhibitors","volume":"75","author":"Gu","year":"2020","journal-title":"Cell. Signal."},{"key":"10.1016\/j.bbrc.2026.154629_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051065","article-title":"Nelfinavir inhibits the TCF11\/Nrf1-Mediated proteasome recovery pathway in multiple myeloma","volume":"12","author":"Fassmannov\u00e1","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbrc.2026.154629_bib16","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/bloodadvances.2020003820","article-title":"Multiple myeloma cells depend on the DDI2\/NRF1-mediated proteasome stress response for survival","volume":"6","author":"Chen","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbrc.2026.154629_bib17","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41419-022-04925-3","article-title":"The aspartyl protease DDI2 drives adaptation to proteasome inhibition in multiple myeloma","volume":"13","author":"Op","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbrc.2026.154629_bib18","article-title":"Cancer statistics","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbrc.2026.154629_bib19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3233\/BLC-201511","article-title":"Systematic review and meta-analysis of cisplatin based neoadjuvant chemotherapy in muscle invasive bladder cancer","volume":"8","author":"Benkhadra","year":"2022","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.bbrc.2026.154629_bib20","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/oncolo\/oyae215","article-title":"Reevaluating the role of platinum-based chemotherapy in the evolving treatment landscape for patients with advanced urothelial carcinoma","volume":"29","author":"Zhang","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.bbrc.2026.154629_bib21","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.21873\/anticanres.15072","article-title":"Ubiquitin-proteasome system is a promising target for killing cisplatin-resistant bladder cancer cells","volume":"41","author":"Okubo","year":"2021","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbrc.2026.154629_bib22","doi-asserted-by":"crossref","first-page":"7598","DOI":"10.1158\/0008-5472.CAN-05-2614","article-title":"Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells","volume":"66","author":"Mlynarczuk-Bialy","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154629_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2023.110840","article-title":"Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine\/cisplatin resistance in bladder cancer","volume":"388","author":"Himura","year":"2024","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bbrc.2026.154629_bib24","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.nutres.2019.10.010","article-title":"Flavonol glycosides of Rosa multiflora regulates intestinal barrier function through inhibiting claudin expression in differentiated Caco-2 cells","volume":"72","author":"Endo","year":"2019","journal-title":"Nutr. Res."},{"key":"10.1016\/j.bbrc.2026.154629_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2024.110135","article-title":"Docosahexaenoic acid enhances the treatment efficacy for castration-resistant prostate cancer by inhibiting autophagy through Atg4B inhibition","volume":"760","author":"Kudo","year":"2024","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bbrc.2026.154629_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/jb\/mvaf022","article-title":"Inhibition of autophagy by Atg7 knockdown enhances chemosensitivity in gemcitabine\/paclitaxel-resistant pancreatic cancer MIAPaCa2 cells","volume":"178","author":"Kudo","year":"2025","journal-title":"J. Biochem."},{"key":"10.1016\/j.bbrc.2026.154629_bib27","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1182\/blood-2008-08-172734","article-title":"The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition","volume":"113","author":"Bianchi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.154629_bib28","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s10238-025-01713-z","article-title":"Impact of proteostasis workload on sensitivity to proteasome inhibitors in multiple myeloma","volume":"25","author":"Sedlacek","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.bbrc.2026.154629_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21010327","article-title":"Disabling the protease DDI2 attenuates the transcriptional activity of NRF1 and potentiates proteasome inhibitor cytotoxicity","volume":"21","author":"Northrop","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2026.154629_bib30","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.freeradbiomed.2025.03.003","article-title":"Deficiency of DDI2 suppresses liver cancer progression by worsening cell survival conditions","volume":"232","author":"Liu","year":"2025","journal-title":"Free Radic. Biol. Med."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26013951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26013951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:47:43Z","timestamp":1792813663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X26013951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":30,"alternative-id":["S0006291X26013951"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154629","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced NRF1-mediated proteasome bounce-back and nelfinavir-mediated bortezomib sensitization in gemcitabine\/cisplatin-resistant bladder cancer cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154629","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"154629"}}